THE ZELVO-PEPTIDE RESEARCH LIBRARY
A dedicated space for the context behind the collection.
Explore selected studies, observation windows and the limits of current evidence.
01 / COMPOUND PROFILES
Compound profiles will bring together the formal name, catalog specification and clearly attributed references. Current catalog entries provide a starting point for discussion.
Explore the collection ↗02 / BATCH DOCUMENTATION
A compound description and a certificate of analysis serve different purposes. A batch document should identify the compound, batch, method and reporting source.
No batch certificate is currently published in this library. Contact zelvo-peptide for the documents relevant to your inquiry.
Ask about documentation ↗03 / SOURCE LITERATURE
Six compounds. Different evidence.
Read the study before interpreting the timeline.
Study observation windows are not guaranteed onset times; trial medicines and topical formulations are not evidence that a catalog research vial will produce the same results.
Body-weight studies do not establish skin benefits. Individual outcomes can vary.
Randomized human trial
72-week study endpoint
SURMOUNT-1 studied adults with obesity or overweight and related conditions, without diabetes. The endpoint describes the trial observation period, not when every individual will notice a change.
Investigational medicine
24 / 48 / 80-week assessments
A phase 2 trial assessed weight outcomes at 24 and 48 weeks; the phase 3 TRIUMPH-1 trial used an 80-week endpoint. These are separate studies, not a personal results schedule. Retatrutide remains investigational.
Limited topical human evidence
56 days / 12 weeks in topical studies
A 56-day study tested a multi-ingredient cream without a clinical control group. A small 12-week post-laser comparison found no objective skin advantage between groups. Neither study establishes an outcome for an injectable research vial.
Limited human evidence
No validated skin or weight timeline
Small human studies concern knee pain and short-term safety. Their follow-up periods do not establish a reproducible skin, weight-loss or tissue-repair timeline for this catalog material.
Human evidence gap
No established human outcome window
A 2026 FDA review found no patient treatment data for TB-500. Full-length thymosin beta-4 topical wound studies concern a different material and route, and cannot establish a timeline for the TB-500 fragment.
Different research endpoints
No validated skin or weight timeline
Small human comparative studies investigated anxiety symptoms, not cosmetic skin improvement or weight loss. They cannot establish either timeline for this catalog material.
Sources reviewed 20 October 2026. These references describe the materials and conditions used by the study authors.